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ABSTRACT 
Cannabinoids have shown diverse and critical effects on the body systems, which alter the physiological functions. 
Synthetic cannabinoids are comparatively innovative misuse drugs with respect to their nature of synthesis. Syn-
thetic cannabinoids therapy in healthy, chain smokers, and alcoholic individuals cause damage to the immune and 
nervous system, eventually leading to intoxication throughout the body. Relevant studies were retrieved using 
major electronic databases such as PubMed, EMBASE, Medline, Scopus, and Google Scholar. The extensive use 
of Cannabis Sativa L. (C. Sativa) and its derivatives/analogues such as the nonpsychoactive dimethyl heptyl hom-
olog (CBG-DMH), and tetrahydrocannabivarin (THCV) amongst juveniles and adults have been enhanced in re-
cent years. Cannabinoids play a crucial role in the induction of respiratory, reproductive, immune and carcinogenic 
effects; however, potential data about mutagenic and developmental effects are still insufficient. The possible 
toxicity associated with the prolong use of cannabinoids acts as a tumor promoter in animal models and humans. 
Particular synthetic cannabinoids and analogues have low affinity for CB1 or CB2 receptors, while some synthetic 
members like Δ9-THC have high affinity towards these receptors. Cannabinoids and their derivatives have a direct 
or indirect association with acute and long-term toxicity. To reduce/attenuate cannabinoids toxicity, pharmaceuti-
cal biotechnology and cloning methods have opened a new window to develop cannabinoids encoding the gene 
tetrahydrocannabinolic acid (THCA) synthase. Plant revolution and regeneration hindered genetic engineering in 
C. Sativa. The genetic culture suspension of C. Sativa can be transmuted by the use of Agrobacterium tumefaciens 
to overcome its toxicity. The main aim of the present review was to collect evidence of the endo-cannabinoid 
system (ECS), cannabinoids toxicity, and the potential biotechnological approach of cannabinoids synthesis.  
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INTRODUCTION 
Humans and animals naturally synthesize 
and exert a group of chemical compounds 
(ligands) named endo-cannabinoids that acti-
vate their receptors located throughout the 
central and peripheral nervous systems. The 
ECS consists of cannabinoid receptors and 
endo-cannabinoids compounds that secrete 
neurotransmitters (NTs) throughout the body 
and especially in the brain. In the 1990s, the 
first and second cannabinoid receptors, CB1 
and CB2 were cloned and classified as the 
member of the family of G protein-coupled 
receptors. The CB1 is found abundantly in 
brain neurons, while CB2 is found primarily 
in cells of the peripheral immune system. 
Maintenance of the homeostatic and physio-
logic functions of the body is considered as 
the major tasks of ECS (Fine and Rosenfeld, 
2013). In addition, phytocannabinoids (exog-
enous plant-derived cannabinoids) are natu-
rally produced ligands in C. Sativa and some 
other plants, of which synthetic cannabinoids 
are synthesized from the ancient time (Pacher 
et al., 2006). The most recognized phytocan-
nabinoids are known as tetra-hydrocanna-
binol (THC); the major psychoactive com-
pound in cannabis (Lambert and Fowler, 
2005; Santos et al., 2015). Other main phyto-
cannabinoids ingredients include: cannabidiol 
(CBD) and cannabinol (CBN). Almost 85 
various cannabinoids have been identified 
and isolated from C. Sativa showing different 
health effects (El-Alfy et al., 2010).  
Few decades ago, it has been understood 
that ECS performs several normal body func-
tions. The potential medical activities of the 
ECS have been explored in the last years. 
Cannabinoids have numerous biological and 
functional properties, which modulate ECS 
with agonists and antagonists with novel ther-
apeutic purposes towards various disorders. 
For instance, ‘anandamide’ has the potential 
to increase food intake in rats (Costa et al., 
1999) and raise the weight in cancer and hu-
man immunodeficiency virus (HIV+) pa-
tients; while ‘SR-141716 A’ as an antagonist 
prohibits food intake (Arnone et al., 1997; 
Colombo et al., 1998; Simiand et al., 1998) 
and acts as a vital anti-obesity remedy which 
functions on CB1 receptors in the hypothala-
mus (Berry and Mechoulam, 2002). 
Within the body, endo-cannabinoids act 
as ligands intended for cannabinoid receptors, 
thus play as neuromodulators role in the brain. 
Ligands are small molecules able to dock onto 
the binding site of the proteins, therefore ac-
complish their ability to regulate the recep-
tors’ function and its downstream biological 
pathways. The basic building block unit of 
endo-cannabinoids are polyunsaturated fatty 
acids, hence the only difference in the chemi-
cal composition from phytocannabinoid of 
the cannabis plant. The well-known endo-
cannabinoid compounds include; anan-
damide, 2-arachidonoylglycerol, 2-arachi-
donylglyceryl ether (noladin ether), O-arachi-
donoyl-ethanolamine (virodhamine) and N-
arachidonoyl-dopamine (NADA) (Groten-
hermen, 2004). Anandamide and NADA are 
not only responsible for binding to canna-
binoid receptors, but also upregulate the abil-
ity of capsaicin, an essential part of hot chili 
peppers, to modulate vanilloids (TRPV1) re-
ceptors. 
Several studies have been revealed that 
cannabinoids stimulate the ECS. During the 
painful situation, the endo-cannabinoids are 
elevated in the periaqueductal gray of the 
brain following painful stimuli. The activa-
tion of cannabinoid receptors, resulting in 
nerve damage was described in the animal 
study of long-lasting neuropathic pain and in-
testinal inflammation. In such conditions, 
cannabinoid agonist effectiveness was en-
hanced (Grotenhermen, 2006). 
The ECS along with biological and phys-
iological properties of cannabinoids has been 
extensively studied in the past decades. It is 
noteworthy that cannabinoids have immune 
modulatory effects and their possible role in 
autoimmune disease and inflammatory ther-
apy has been investigated. However, the main 
aim of this review was to collect evidence of 
ECS and toxicity of cannabinoids with the po-
tential biotechnological approach of canna-
binoids. 
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METHODS 
Search strategy 
The studies comprised in present review 
have been retrieved from the PubMed data-
base of the National Library of Medicine, 
Scopus, EMBASE, Medline and Google 
Scholar by setting limits for papers published 
mostly from 1990 onwards, however few be-
fore, using the keywords “endo-cannabinoids 
system”, “biotechnology and cannabinoid”, 
“toxicity of cannabinoids”, “acute toxicity of 
cannabinoids”, “moderate effects of canna-
binoids”, “chronic effects of cannabinoids”, 
and “cannabinoids and immune system”. This 
bibliographic search retrieved 250 studies 
(Figure 1). 
 
Exclusion and inclusion criteria 
Criteria for exclusion were the reports in 
languages other than English, studies for 
which abstract was not present, reports con-
cerning to the association of cannabinoids 
with studies other than death and the immune 
system. Most studies, which investigated the 
relation of toxicity of cannabinoids on the 
non-cannabinoid system, were also excluded. 
The studies, which focus on single or limited 
cases having adverse effects without showing 
a clear role of cannabinoids in the toxicologi-
cal pathogenesis, were also excluded. Eventu-
ally, a total number of 195 reports indexed in 
Google Scholar and/or PubMed were found to 
gratify the criteria of inclusion. Various stud-
ies not indexed in PubMed were obtained by 
manual searching in Google Scholar, and 
such reports which satisfied the criteria for in-
clusion were further retrieved. Therefore, the 
total number of studies (n) included in this re-
view reached 169 (Figure 1). 
 
The ECS 
In short, cannabinoid receptors, their en-
dogenous ligands and the enzymes that syn-
thesize and degrade endo-cannabinoids con-
struct the ECS (Mackie, 2008). The following 
sections will focus on the cannabinoid recep-
tors such as CB1 and CB2 along with other 
non-CB receptors, which exert their effects by 
regulating NTs and cytokine release. 
 
 
Figure 1: Flow diagram of included studies. The flow chart depicts the number of citation and resource 
materials that have been screened, excluded and/or included in the review. 
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Cannabinoids receptor agonists 
Today, several compounds have been pre-
pared capable of acting as agonists against 
both cannabinoid receptors. On the basis of 
heterogeneous chemical structure, canna-
binoid receptor agonists are categorized into 
four types of groups such as: classical, non-
classical, eicosanoid and aminoalkylindole 
compounds as shown in the Figure 2 (Howlett 
et al., 2002; Pertwee, 2005). Briefly, the clas-
sical group involves phytocannabinoid (Δ9-
THC, cannabinol) and their synthetic deriva-
tives. The non-classical group consists of bi-
cyclic and tricyclic analogues of Δ9-THC that 
lacks a pyran ring such as P55940, HU-308, 
CP47497, and CP55244. The endo-canna-
binoids produced by our body cells is catego-
rized in the eicosanoid group. These endo-
cannabinoids stand for arachidonoylethanola-
mide, O-arachidonoylethanolamine, 2-arachi-
donoyl glycerol, 2-arachidonyl glyceryl, and 
numerous other synthetic analogues of anan-
damide. Aminoalkylindole comprises of 
WIN5512.  
The cannabinoids mostly act on two im-
portant receptors of the ECS, CB1 and CB2 
receptors. Each cannabinoid has its own affin-
ity for the specific receptors (Howlett et al., 
2002; Pertwee, 2005). For example, Δ9-THC 
has a high affinity towards CB1 receptor, 
while cannabinol is an agonist without 
marked CB1/CB2 selectivity (Figure 2). 
 
Cannabinoid receptors 
Cannabinoid receptors CB1 and CB2 
Generally, CB1 receptors are mostly pre-
sent in several brain regions; more precisely 
exist in the basal ganglia, in the limbic system 
comprising the hippocampus and to a lesser 
extent in other parts of the body (Pacher et al., 
2006). These receptors mediate many of the 
psychoactive effects of cannabinoids 
(Mackie, 2008). CB1 receptors have also been 
observed in the cerebellum and in both male 
 
 
 
Figure 2: Agonists and antagonists of cannabinoids receptors. Both CB1 and CB2 receptors of agonists 
and antagonists classes have been illustrated. Synthetic derivatives such as HU-210, CP 55/950 and 
HU-308 are the most efficient compounds used for pharmacological purpose.  
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and female reproductive systems. CB2 recep-
tors have shown more restricted distribution, 
being found in the immune system and in a 
few neurons, with extremely high quantity in 
the spleen. They are also expressed by micro-
glia in the human cerebellum (Núñez et al., 
2004; Pacher and Mechoulam, 2011). Animal 
studies have shown that CB2 receptors might 
be responsible for their anti-inflammatory and 
other therapeutic activities (Pacher and 
Mechoulam, 2011). Theoretical overview, 
physiology, functions and applications of 
these receptors have been discussed exten-
sively by researchers. 
Synthetic cannabinoids acting on CB1 
and CB2 receptors as agonists exhibit their 
therapeutic effects such as anti-inflammatory, 
bronchodilation, anti-allergic effects, neuro-
protection, antineoplastic, appetite stimulator, 
pleasure sensation, mood, memory, immune 
system stimulator, anti-nausea properties, and 
pain killer, while restraining the psychoactive 
properties (Grotenhermen, 2004). Synthetic 
cannabinoids inhibit the excess NTs at the 
junction of pre- and post-synaptic neurons, 
which ultimately mimic the effects of endo-
cannabinoids (Figure 3). The therapeutic ef-
fects of cannabinoids are also attributed to 
generating extensive toxicity in different sys-
tems (Gurney et al., 2014). During the past 
decade, it was discovered that synthetic can-
nabinoids have a higher affinity towards CB2 
receptors. Toxicology laboratories around the 
globe have made intensive efforts to keep up 
with the rate, at which cannabinoids are de-
signed and marketed (Zawilska and 
Wojcieszak, 2014). However, for the assess-
ment of pharmacokinetics limitations, inade-
quate data of controlled studies do exist 
(Kronstrand et al., 2013). The association be-
tween the influence and the concentration of 
cannabinoids is not clearly well-defined. 
 
 
 
Figure 3: Mechanism of action of the cannabinoids at pre- and postsynaptic terminal. 1). NT from 
presynaptic neuron triggers the postsynaptic neuron. 2). Stimulated postsynaptic neuron releases 
endo-cannabinoids. 3). Endogenous CB1 ligand disseminates back to and binds to the presynaptic 
CB1 receptor. 4). CB1 receptor stimulates a G-protein, leading to inhibition of neurotransmitter re-
lease. 5). Synthetic cannabinoids are thought to activate CB1 receptors directly, imitating the effects 
of endo-cannabinoids. 
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Mechanism of action of CB1 and CB2  
receptors 
The binding of heterotrimeric Gi/o proteins 
to CB1 and CB2 receptors produce various ef-
fects. The activation of G alpha i/o proteins 
triggers CB1 receptors to exhibit their effects. 
The inhibition of adenylate cyclase enzyme 
occurs due to the coupling of CB1 to its ago-
nists. Similarly, increase in the level of mito-
gen-activated protein kinase (MAPK) causes 
lowering of intracellular cAMP level due to 
binding of CB1 and its ligands. In certain sit-
uations, due to the activation of CB1 receptors 
attached to Gs proteins stimulate adenylate 
cyclase-cAMP (Di Marzo, 2008; Pertwee, 
2006). CB1 and CB2 receptors also are in-
volved in a variety of ion channels in the cell 
membrane, which are completely penetrating 
correct the calcium and potassium channels. 
The binding of cAMP-dependent intact of re-
ceptors with molecules such as c-Jun, c-fos, 
p38, N-terminal kinase (JNK), extracellular 
signal controlled kinase (ERK), Rf-1, protein 
kinase-C (PKC) and protein kinase p (PKA), 
so these calcium and potassium channels are 
stimulated (Pagotto et al., 2006). In the case 
of CB1, initiation can lead to lessening of 
Ca2+ ion access into the cell, without the pres-
ence of cAMP, which is necessary for the NT 
release. As a whole, they would affect a de-
crease in the release of NTs. Therefore, in 
dose-response relationship manner, CB1 re-
ceptor is a pre-synaptic junction that moder-
ates the release of NTs (Howlett, 2005).   
CB1 and CB2 cannabinoid receptors also 
have the ability to control phosphorylation 
and initiate many members of MAPKs, such 
as p38 MAPKs, c-Jun, extracellular signal-
regulated kinase-1 and -2 (ERK1/2). Besides, 
this MAPK also regulates gene expression as-
sociated with cell motility, proliferation, 
apoptosis and glucose metabolism (Howlett, 
2005). The involvement of endogenous, ex-
ogenous and synthetic agonists with CB1 and 
CB2 receptors produces their desirable ef-
fects. After the anticipated effects, agonist 
molecules are rapidly neutralized by entry 
into the cells and are metabolized. The meta-
bolic process of hydrolysis of 2-AG by mono-
glyceride lipase or enzymatic hydrolysis with 
the help of fatty acid amide hydrolase enzyme 
(FAAH) metabolizes anandamide (Di Marzo, 
1998; Dinh et al., 2002; Giuffrida et al., 
2001).  
 
Cannabinoid receptors and their regulations 
CB1 receptors are located in particular 
non-neuronal cells and in all central and pe-
ripheral neurons (Howlett et al., 2002; 
Pertwee, 1997, 2005). In the central nervous 
system (CNS), the dissemination patterns of 
the CB1 receptors are heterogeneous and 
linked to their function. CB1 receptors are 
abundantly present in the cerebellum, en-
topeduncular nucleus, globus pallidus, sub-
stantia nigra pars reticulate, caudate-putamen, 
hippocampus and cerebral cortex along with 
some parts of the spinal cord and other areas 
of the brain. They are involved or modulate in 
pain sensation due to stimulation of the nerve 
cells. Different studies suggested that the 
presence of CB1 receptor agonist in CNS trig-
gered to alter the ability of perception, 
memory as it regulates motor function and to 
initiate anti-nociception (Iversen, 2003; 
Pertwee, 1997, 2005; Pertwee et al., 2000). 
The CB1 receptors located in the central and 
peripheral nerve ending control the release of 
inhibitory and excitatory NTs activation 
(Howlett, 2005; Pertwee, 2005). CB2 recep-
tors present in the immune cells are responsi-
ble for immunomodulation (Howlett et al., 
2002; Pertwee, 1997). Both CB1 and CB2 re-
ceptors regulate each other activities to re-
lease chemical messengers in the appropriate 
level. By the interaction of cannabinoids, CB1 
receptors release NTs at the CNS and control 
their release, while CB2 regulate the release 
of inflammatory cytokines, modulating the 
immune system (Marsicano et al., 2002).  
 
Other cannabinoid non-CB1 and non-CB2 
receptors of the ECS 
Vanilloid receptors 
There is a non-CB receptor, which has the 
cannabinoids’ conjugation capacity known as 
EXCLI Journal 2017;16:688-711 – ISSN 1611-2156 
Received: March 07, 2017, accepted: April 29, 2017, published: May 15, 2017 
 
 
694 
capsaicin or TRVP-1 receptor. Capsaicin re-
ceptors are mainly present in the nociceptive 
neurons of peripheral nervous system, how-
ever, they have been found in many other tis-
sues involving the CNS. Capsaicin is mostly 
involved in the spreading and regulation of 
neuron pain through perivascular and primary 
afferent neurons (De Petrocellis and Di 
Marzo, 2009; Devane et al., 1992; Di Marzo 
and Petrosino, 2007). It has been illustrated 
the conjunction of endogenous cannabinoid 
anandamide with capsaicin receptor leads to 
the release of substance-P and calcitonin 
gene-related-P (CGRP), which exerts a local 
vasodilation, allogeneic and pro-inflamma-
tory effects along with advantageous actions 
like cardio-protection and anti-hypertensive 
properties (Ahluwalia et al., 2003; Hwang et 
al., 2000; O'Sullivan et al., 2004; Price et al., 
2004; Shin et al., 2002; Tognetto et al., 2001; 
Zygmunt et al., 1999).  
Non-CB1, non-CB2 and non-vanilloid  
receptors 
Few studies have revealed that various bi-
ological activities of the cannabinoids are dif-
ficult to be reversed by CB1 and CB2 antago-
nists. To achieve this goal, many other recep-
tor pathways such as G-protein receptor-55 
(GPR-55), nicotine, adenosine A-2-A and pe-
roxisome proliferator-activated receptors 
(PPARs), have been identified for canna-
binoids signalling transduction (Klein, 2005; 
Lazzerini et al., 2012).  
Allosteric location of cannabinoids 
Besides the aforementioned receptors, 
there are several allosteric sites for anand-
amide and other cannabinoids on the numer-
ous non-cannabinoid receptors (Pertwee, 
2003, 2004, 2005). These allosteric sites in-
clude M1/M4 muscarinic receptors, α1-adre-
noceptors, 5-HT3, 5-HT2, α-amino-3-hy-
droxy-5-methyl-4-isoxazolepropionic acid 
(AMPA), GLUA-1 and GLUA-3 glutamate 
receptors (Akinshola et al., 1999a, b; Barann 
et al., 2002; Cheer et al., 1999; Christopoulos 
and Wilson, 2001; Fan, 1995; Godlewski et 
al., 2003; Oz et al., 2002). However, there is 
no evidence of the biological significances of 
allosteric sites on M1/M4 receptors by anan-
damide and methanandamide or SR141716A 
and 5-HT2 receptors by HU-210 (Pertwee, 
2005). 
 
Effects of cannabinoids  
There are various effects of cannabinoids 
on the body systems, which includes muscle 
relaxation, anti-inflammation, anti-allergic, 
sedative, neuroprotective, anti-emesis and 
antineoplastic properties (Grotenhermen, 
2004). However, the next section would only 
discuss the interaction of cannabinoids with 
CNS.  
 
Cannabinoids and CNS 
The cannabinoids also show their poten-
tial effects on the CNS interrelating with var-
ious NTs and neuromodulators such as hista-
mine, serotonin, glutamate, norepinephrine, 
prostaglandins, opioid peptides, acetylcho-
line, dopamine and gamma-amino butyric 
acid (GABA) (Baker et al., 2003; Dewey, 
1986; Grotenhermen, 2004; Pertwee, 1992). 
Some of the biological activities and benefi-
cial effects of THC can be elucidated by these 
correlations. For example, tachycardia and 
hypo-salivation with dry mouth are facilitated 
by the effects of THC on the release and turn-
over of acetylcholine (Domino, 1999; Mattes 
et al., 1994). Serotonin interacts with canna-
binoids having anti-emetic properties (Fan, 
1995). The interactions of cannabinoids with 
dopamine, glutamate, and GABAergic trans-
mitter systems are attributed to spasmodic 
conditions (Grotenhermen and Russo, 2013). 
The inhibition of surplus glutamate produc-
tion, prohibition of calcium influx into the 
cells and antioxidant properties of neuropro-
tective cannabinoids were detected in animal 
models, which lessen the level of oxygen rad-
icals and the modulation of vascular tone 
(Grundy, 2002; Grotenhermen and Russo, 
2013). In addition, cannabinoids are also stud-
ied for stroke and brain damages. 
 
Cannabinoids’ analogues 
CBG-DMH, an analogue of cannabinoids, 
is showing hypotensive and vascular relaxant 
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properties (Maor et al., 2005). The CB1/2, 
vanilloid receptor antagonists and nitric oxide 
synthase do not prevent vascular relaxation 
induced in the abdominal aorta of rat by CBG-
DMH, due to pertussis toxin sensitivity. 
CBG-DMH reduces nitric oxide production 
and tumor necrosis factor (TNF) in murine 
macrophages. However, the effect of hypo-
tension is unclear; it may be correlated with 
an abnormal cannabinoid, a CBD isomer, 
which inhibits the effect of these compounds 
(Vanessa Ho and Hiley, 2003). Furthermore, 
CBD has not the capability to prevent mecha-
nism of hypotension induced by THC, while 
hypotension may follow some new mecha-
nisms.  
Another plant origin propyl analogue of 
THC is THCV, which is an antagonist of 
anandaminde and WIN-55212. THCV plays 
its role on the basis of the selectivity, which 
prevents the effect of both agonists in the vas 
deferens than brain membranes (Ashton, 
2001; Begg et al., 2005). The influence of 
THCV is proven to be more potent for antag-
onizing the effect of WIN and anandamide on 
electrically induced contractions of the vas 
deferens than provoking the inhibition initi-
ated by THC (Ashton, 2001). 
At 3–1000 nanomol (nM), THCV did not 
prevent electrically induced contractions of 
mouse isolated vas deferens; though, the 
amount of THCV in this range formed dextral 
shifts in the log concentration–response 
curves of WIN and anandamide for electri-
cally evoked contractions. These changes 
were not convoyed by a reduction in the max-
imal effect of any agonist. Nevertheless, at 3 
millimolar (mM), THCV did lessen the con-
tractile reaction of the vas deferens in a CB1 
receptor antagonist (SR141716)-independent 
way. Moreover, THCV looks like SR141716 
antagonist, which at high quantities also co-
operates with non-CB1 targets (Mechoulam, 
2005). 
It has been established that very little dose 
of anandamide (0.0001–0.1 mg/kg), which 
had negligible effects when administered 
alone, partially or fully inhibited THC-in-
duced effects (Fride et al., 1995). It has been 
shown (Bayewitch et al., 1996) that THC an-
tagonizes the agonist-induced inhibition of 
adenylyl cyclase-mediated by the CB2 recep-
tor and determined that THC constitutes a 
weak antagonist for this receptor under the 
circumstances of their experiments. 
 
Medical application of cannabinoids and 
their effects on immune function 
Over the years, various studies have been 
conducted concerning cannabinoids, their 
roles in ECS and possible therapeutic actions. 
It has been proved that cannabinoids propose 
several physiological properties and their 
multiple agonists and antagonists exhibit val-
uable potentials in various diseases. The ther-
apeutic footprints of cannabinoids have been 
traced in cancers, diabetes, rheumatoid arthri-
tis, multiple sclerosis, glaucoma, allergic 
asthma, dystonia, spinal cord injuries, analge-
sia, Tourette's syndrome in humans, nausea 
and epilepsy (Amar, 2006; Grotenhermen and 
Müller-Vahl, 2012). Cannabis-based medica-
tions possess their effects via the activation of 
cannabinoid receptors. The conduction of var-
ious controlled clinical trials has led to the ap-
proval of several cannabis-based medicines 
(dronabinol, nabilone and a cannabis extract 
[THC: CBD=1:1]) in several countries 
(Grotenhermen and Müller-Vahl, 2012). Be-
side cannabis, some other herbs such as 
Ephedra sinica, Cissus quadrangularis, 
Momordica charantia and Zingiber officinal 
also act on cannabinoid receptors (Hasani-
Ranjbar et al., 2009).  
The immune system is a complex set-up 
of many biological structures and functions 
such as cells, cytokines, hormones, tissues 
and physiological processes that protects the 
body against diseases. The presence of canna-
binoid receptors on cells of the immune sys-
tem, evidence-based immunomodulatory ef-
fects of cannabis in vivo, and in vitro studies 
of immune cells (e.g. T cells and macro-
phages), strongly support the idea that canna-
binoids are able to adjust both the function 
and secretion of cytokines from immune cells. 
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Therefore, cannabinoids seem to be a poten-
tial candidate to treat various inflammatory 
disorders (Croxford and Yamamura, 2005).  
New findings from Cabral et al., (2015) 
showed drugs like cannabinoids are able to 
modulate various cytokines, corticosteroids 
and colony-stimulating factors, which are re-
sponsible for the maturation of the stem cells 
to the competent mature lymphocytes. The 
thymus and bone marrow are known as the 
main responsible lymphoid organs capable to 
convert stem cells to the mature lymphocytes. 
This maturation of stem cells to the immune 
cells is very essential to identify and distin-
guish non self-antigens from foreign antigens 
instead of self-antigens, therefore reduces au-
toimmunity (Cabral et al., 2015). Mature lym-
phocytes leave the bone marrow and thymus, 
and transfer to the supplementary lymphoid 
organs (spleen, lymph node, blood, skin, 
bronchial lymphatic tissue and gut associated 
lymphatic tissue). As, after the entrance of 
foreign microbes/antigens, the immune re-
sponse is triggered by binding cellular ele-
ments of immunity (macrophages, dendritic 
cells, neutrophils, mast cells, eosinophil, ba-
sophils, T and B cells) with microbes. Hor-
mones and mediators are mainly responsible 
for the cellular elements in the bone marrow 
and thymus. Furthermore, the interactions of 
cellular elements with antigens/microbes are 
effected by cannabinoids. Certain effector 
functions such as cell-mediated immunity, an-
tibody production, signs of allergy, autoim-
munity, interleukins and cytokine production 
linked with mixture of biological active com-
posites like endorphins and anandamide (can-
nabimimetics) are initiated by antigens 
(Eisenstein and Meissler, 2015; Kaplan, 
2013; Newton, 2001).  
The interaction of an antigen with cyto-
kines or the effector functions provides differ-
ent entry points at which normal immune ho-
meostasis alters, that makes the drug’s effects 
long and difficult process, as cannabinoids 
and other drugs conjugate. The immune sys-
tem has the potential to produce, secrete, 
carry and metabolize cannabinoids due to the 
presence of CB1 and CB2 receptors (Bisogno 
et al., 1997; Cabral and Staab, 2005; Klein et 
al., 2003; Pestonjamasp and Burstein, 1998). 
The expression pattern of these receptors is 
different in each immune system cells. The 
expressions of these receptors increase in or-
der of; CD4 cells, monocytes, CD8 cells, neu-
trophils, natural killer cells (NK) and B cells. 
This tendency of expression has been detected 
in mouse splenocytes (Bouaboula et al., 
1993). The expressions of receptors on im-
mune cells are influenced by cell activation 
state and immune stimulation (Lee et al., 
2001). Multiple studies have shown that ex-
ogenous cannabinoids have a vital role in im-
munosuppression affecting ECS, as a novel 
therapy for autoimmune and inflammatory 
disease (Berdyshev, 2000; Cabral and Staab, 
2005; Klein et al., 2003; Kumar et al., 2001).  
The escalation of T helper-2 (Th2) cells 
and lessening Th-1 reactions, also control Th-
1/2 balance by the effect of Δ9-THC (Klein et 
al., 2000; Newton et al., 1994; Yuan et al., 
2002; Zhu et al., 2000). Though, the therapeu-
tic effect of Δ9-THC is limited due to its psy-
choactive effects, somehow, cannabidiols 
show no psychoactive effects due to their low 
affinity towards CB1 and CB2 receptors 
(Munro et al., 1993; Thomas et al., 1998). On 
the other hands, chronic administration of 
cannabidiols is tolerable without showing 
side effects (Consroe et al., 1991). Both in 
vivo and in vitro investigations have demon-
strated that four main pathways engage in im-
mune suppression of cannabinoids as; initia-
tion of apoptosis, prevention of cell propaga-
tion, prevention of mediators, as well as cyto-
kine synthesis and stimulation of T-cells reg-
ulatory system (Rieder et al., 2010). 
Different studies regarding revealed that 
anandamide initiate apoptosis in lymphoma 
U-937 cells, human neuroblastoma CHP-100 
cells and mitogen-induced T and B human 
lymphocytes through a completely dose-de-
pendent manner (Marsicano et al., 2002; 
Schwarz et al., 1994). It has been illustrated 
that in murine macrophages and T-cells apop-
tosis was initiated, through the caspase activ-
ity and regulation of BCl2 by Δ9-THC (Zhu et 
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al., 1998). Yet, no such evidence of canna-
binoids’ presentations in induction of apopto-
sis in vivo, as its challenging to determine 
apoptosis due to the quick and effective clear-
ance through phagocytes (Rieder et al., 2010). 
Mice had been injected with Δ9-THC 
showed reduction in spleen and thymus cellu-
larity, affecting various cells, such as macro-
phages, T- and B-cells (McKallip et al., 
2002). Likewise, the low concentration of Δ9-
THC stimulated AnnexinV+ cells, exhibiting 
early apoptosis, but at higher doses, there was 
late apoptosis and necrosis due to spleen cell 
had both AnnexinV and PI positive. Δ9-THC 
could alter immature lymphocyte instead of 
active lymphocytes, also the amount of apop-
tosis reported to be higher in THC treated cul-
ture than Δ9-THC and mitogen cultures 
(McKallip et al., 2002). Accordingly, it is 
noteworthy that activated lymphocytes can 
suppress the expression of CB2 receptor and 
decrease their sensitivity to Δ9-THC. Inges-
tion of CB2 antagonist blocks Δ9-THC-acti-
vated programmed cell death in thymus cells 
and lymphocytes, so it’s observed that Δ9-
THC triggers apoptosis via CB2 receptor, 
while CB1 has no role in this significant effect 
(McKallip et al., 2002). Cannabidiol induces 
apoptosis in CD4+ and CD8+ cells, murine 
thymocytes and EL-4 cells, depending on its 
concentration and the duration of the experi-
ment. Cannabidiol also initiates apoptosis 
through the production of reactive oxygen 
species (ROS) and stimulating caspase-8 and 
-3 (Lee et al., 2008).  
In vitro studies have shown the high doses 
of Δ9-THC inhibit responses to lipopolysac-
charide (LPS), T-cell mitogens and anti-CD3, 
while lower doses of Δ9-THC trigger T-cells 
(Klein et al., 1995). The cannabinoids possess 
a double-phase role in increasing of the pro-
liferation of B-cells in response to Δ9-THC 
(Derocq et al. 1995), however, another trail 
indicated a significant decline in response of 
B-cells to the LPS after cannabinoid therapy 
(Klein et al., 1995). Cannabidiol improves the 
production of interleukin-4 (IL-4), IL-10 and 
Th2-associated cytokines along with de-
creases in IL-1, IL-12, TNF-α and interferon-
gamma cytokines in the peripheral blood 
mononuclear cells (Weiss et al., 2006). Can-
nabidiol similarly modifies tissue cyclooxy-
genase (COX) activity and prostaglandin E-2, 
while Δ9-THC has the potential to change the 
critical Th1 immunity to defensive Th2 im-
munity, though it would be less efficient than 
cannabidiol (Berdyshev, 2000; Cabral and 
Pettit, 1998; De Filippis et al., 2008; Munson, 
1975; Toguri et al., 2014; Watzl et al., 1991). 
Δ9-THC showed their positive immunosup-
pressive effects in Legionella peumophila 
(Lp) infested dendritic cells. Immune sup-
pression was observed in the Lp-dendritic 
loaded cell pre-treated with Δ9-THC. Inhibi-
tion of the maturation markers such as; CD40, 
CD86, and major histocompatibility com-
plex-II (MHCII) were seen, as Δ9-THC inhib-
ited IL-12p40 production by dendritic cells 
(Lu et al., 2006). 
The T-regulatory cells are resistant to 
apoptosis distinct from other T-cells induced 
by Δ9-THC, and may overturn the T-cells that 
ultimately emit from apoptosis, so further 
studied are needed (Hegde et al., 2008; Rieder 
et al., 2010). Several investigations have ex-
posed cannabinoids’ receptor ligands can in-
hibit distribution, cytolysis, mediators prolif-
eration, phagocytosis and antigen expression 
in the mouse peritoneal macrophages (Cabral 
and Mishkin, 1989; Carlisle et al., 2002; 
Gokoh et al., 2005; Lopez-Cepero et al., 
1986; Maresz et al., 2005). Additionally, in 
vivo and in vitro trials suggested canna-
binoids’ receptor ligands have the power to 
suppress natural killer (NK) cells and the cy-
tokine effector functions (Fischer-Stenger et 
al., 1992; Pross et al., 1992; Wang et al., 
1991). Besides above mentioned evidence, 
some studies also proposed that cannabinoids 
have pro-inflammatory effects such as en-
dorsing allergic reactions, release of inflam-
matory cytokines through CB1 receptor in 
mast cells and enhance B-cells production 
(Klein et al., 1995; Samson et al., 2003; 
Small-Howard et al., 2005; Ueda et al., 2007). 
In optimum concentration, the cells involved 
in acute and chronic inflammation along with 
inflammatory reactions can lead to induce 
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programmed cell death in immune cells 
through cannabinoids.  
 
Toxicity of cannabinoids 
Acute effects  
The short-term cannabinoids’ exposure 
causes very limited toxicity, without eventual 
death due to direct or instant use of recrea-
tional herbal medicine. Statistics indicates 
that six deaths occurred due to vomiting in up-
per respiratory tract, pneumonitis and heavily 
congested lungs, which involved drug intoxi-
cation (ethanol, THC, and JWH-018). The 
most prominent noxious reported effect of 
cannabis (short-exposure) would be on the 
cardiovascular system, which shows signifi-
cant elevation of heart rate and blood pressure 
falling. Accordance with, individuals with a 
history of coronary heart diseases, atheroscle-
rosis, cardiomyopathy and other serious car-
diovascular diseases are at high risk to canna-
binoids toxicity and such subjects (animal 
model or human) should probably be elimi-
nated from clinical trials of cannabinoids’ 
base studies (Hartman and Huestis, 2013; 
Nunez and Gurpegui, 2002). Cannabis/canna-
binoids short-term effect also involves ex-
treme excitement, which is associated with al-
cohol and recreational users. Treating individ-
uals with cannabis/cannabinoids show(s) 
their undesirable side effects along with ben-
eficial properties. Heavy usage of cannabis 
may damage the intellectual and psychomotor 
functions being an imperative matter from the 
public health perspective. The psychomotor 
function impairment stands from a few hours 
(h) to 48 h after taking cannabinoids. Individ-
uals compensate for their damages and take 
less treatments as compared to alcohol tends 
to boost people to the higher risks and aggres-
siveness (Cohen et al., 2012; Nunez and 
Gurpegui, 2002).  
In a study, it was found in road traffic ac-
cidents, blood sample analysis indicated 8 % 
positive for cannabis/cannabinoids, with 
10 % fatalities of whom were driving. How-
ever, these numbers are controversial, as 22-
25 % of cannabis drivers also show the evi-
dence of alcohol consumption as well 
(Hartman et al., 2015; Sewell et al., 2009). In 
the same study, cannabis was positive among 
alcohol positive drivers were as high as 75 %. 
In this assessment, it was shown the major ef-
fects of cannabinoids practice on driving, may 
increase the damages that are activated by al-
cohol. In another survey, 1,333 cannabinoids’ 
individuals were examined, users have low 
accident reports than the general population; 
those of the highest accident rates were shown 
to be multiple drug addicts. It is challenging 
to observe cannabinoids toxicity, as little 
quantities of cannabinoids release from fatty 
tissue into the blood stream (Gurney et al., 
2014; Hartman and Huestis, 2013; Musshoff 
et al., 2014; Yeakel and Logan, 2013). First 
exposure to cannabis with a single dose or 
overdose in routine individual induces psy-
chological effects such as anxiety, fear, mania 
and illusion. Cannabinoids may also lead to 
lifelong psychotic effects, including illusions 
and the phantasms, which may be misdiag-
nosed as schizophrenia. Nonetheless, these 
special effects of cannabinoids are not life-
threatening, but cannabis therapy should not 
be prescribed in these individuals, which may 
cause serious toxicity when used with other 
drugs due to drug-drug interaction (D’Souza 
et al., 2009). The dysphoric reactions of can-
nabis lead to diverse conditions including; ag-
itation, depersonalization-derealization syn-
drome, fright and loss of sense (Johns, 2001). 
It is probably associated with frightening re-
action analogous to post-traumatic stress dis-
order.  
Chronic effects  
The extensive uses of cannabinoids have 
long-term effects on brain functions. Several 
studies had illustrated that cannabis can affect 
the attitude, memory, psychomotor perfor-
mance, sleep, electroencephalogram (EEG), 
heartbeat, arterial pressure, body temperature 
and emesis (Gorelick et al., 2012; Hollister, 
1986; Lichtman and Martin, 2005). The with-
drawal symptoms of cannabis are related to 
that of alcohol and opioids such as anorexia, 
muscular tremors, sleeplessness, dysphoria, 
nervousness, induced reflexes and restless-
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ness. The common signs and symptoms in-
clude; weight loss, salivation, loose bowl 
movements, increased intraocular pressure 
and nausea (Budney and Hughes, 2006). 
Chronic cannabis consumption may also 
cause psychopathological effects such as sus-
picious ideation, illusion and hallucination in 
both psychiatric and non-psychiatric public 
subjects (Bersani et al., 2002). A cannabis 
user develops tachycardia with peripheral 
vasodilatation, which subsequently induces 
hypotension and reduces body temperature. 
Moreover, individuals with a history of previ-
ous cardiovascular diseases may be provoked 
by cannabinoids. Nevertheless, even in young 
men with cardiac infarction, transient is-
chemic attacks and myocardial ischemia have 
been observed (Reece, 2009). The constitu-
ents of cannabis and cigarette smoke are sim-
ilar, except nicotine in tobacco causing car-
cinogenicity of the respiratory tract. The 
mainstream smoke of cannabis extensively 
contains benzanthracenes and benzpyrenes, 
which both are characterized as a human car-
cinogen (De Oliveira et al., 2008). Cannabis 
has similar effects to down-regulate humoral 
and cell-mediated immunity like tobacco. 
Limited in vitro and in vivo investigations ex-
hibited that cannabis alters the bactericidal ac-
tivity of lung macrophages and may reduce 
respiratory antibacterial defensive system 
(Tanasescu and Constantinescu, 2010). THC 
as an eminent cannabinoid binds with an an-
drogen receptor and acts as an antiandrogenic 
compound. It is proven that long-term expo-
sure to cannabinoids leads to lower sperm 
counts, sperm motility and abnormal sperm 
morphology (Park et al., 2004). Chronic use 
of cannabis enhances prolactin concentration 
causing galactorrhea and gynecomastia in 
women and men respectively.  
Adverse effects in clinical use 
Various classes of cannabinoids such as 
nabilone, nabiximols and THC are frequently 
prescribed in clinics. The most common ad-
verse effects of such drugs in recommended 
doses are sedation, lethargy and dizziness. 
While, the observed effects were excitation, 
dysphoria, nervousness, despair, cerebral re-
tardation, recall impairment, obsession and 
hallucination (Arnold, 2015). It seems recom-
mended doses are mostly prescribed in higher 
levels as is needed for ill and old patients, 
therefore, harmful and undesirable conse-
quences could be prohibited from consuming 
small doses. Generally, nabilone is available 
in 1 mg, which is 10 times more effective than 
THC and has a fewer half-life than THC. The 
plasma removal half-life of parental drugs is 
estimated to be 2-4 h, whereas those of its me-
tabolites are 20 h, so 84 % of a single dose is 
removed in 7 days. It is noteworthy that na-
bilone should be kept away and inaccessible 
to children and adolescents due to widespread 
recreational use of it. Different observations 
have indicated nabilone has slight abuse po-
tential; but in higher doses the euphoric ef-
fects are 7 times more severe than THC (Hall, 
2015).  
The wide distributions of cannabinoids’ 
receptors in the body have many adverse and 
beneficial effects. In a systematic review, it 
has been revealed that cannabinoids have 8, 
371 adversarial effects, as 3, 592 were from 8 
observational studies and 4, 779 were indi-
cated in 23 randomized controlled trials 
(Wang et al., 2008). The intensity of adverse 
effects was 16.5, 16.5 and 15.2 % for respira-
tory, gastrointestinal and nervous system, re-
spectively in cannabinoids assigned groups, 
whereas 30 % nervous system conditions 
mostly stayed in control groups (Wang et al., 
2008). In cannabinoids users, 15 deaths were 
recorded of which 3 belonged to the control 
group, though the data was non-significant 
and did not prove that cannabinoids’ toxicity 
was the exact cause. The incidences of severe 
and non-serious adverse effects reported were 
higher in cannabinoids users than controls.  
 
Cannabinoids unpredicted attribution  
towards death 
Synthetic cannabinoids show typical signs 
and symptoms as the natural ones (Gunderson 
et al., 2012; Hoyte et al., 2012; Lemos, 2014). 
In several case studies, death has been re-
ported as the direct consequences, attributed 
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to synthetic cannabinoids’ consumption 
(Behonick et al., 2014; Saito et al., 2013; 
Schaefer et al., 2013). Multiple studies illus-
trated that 4’-methyl-AM-2201 (MAM-2201) 
is a potent agonist for the cannabinoid recep-
tors, which has been systematically deter-
mined in different bio-specimens and no indi-
cation of internal or external diagnostic disor-
der has been reported, but still death occurred 
due to this drug consumption. The use of 
herbal blend cannabinoids has initiated sei-
zures. Toxicological analysis of blood sam-
ples exhibited existence of five different 
herbal cannabinoids along with 250 ng/mL 
amphetamine. Drug intoxication of endo-, 
phyto-, and synthetic-cannabinoids have at-
tributed to the contributory risk factor of 
death (Labay et al., 2016).  
Along with the secretion of endo-canna-
binoids, physiological cytokines and behav-
ioral toxicity are initiated due to canna-
binoids’ practice; so, determination of cause 
and manner of death is essential. Pathological 
findings, toxicity, initial cause and manner of 
death in 25 cases are described in Table 1. The 
clinical findings and analytical identifications 
of various cannabinoid compounds were 
found in the individuals. In 2016, synthetic 
cannabinoids manufactured by Portuguese 
Pharmaceutical Company Bail were tested on 
human volunteers. After progressive comple-
tion of phase-I clinical study of animals, the 
drug was tested on six (6) humans for the first 
time to ensure safety. Head of Neurology, 
Pierre-Gilles Edan reported that after the ad-
ministration, one (1) out of six (6) became 
brain-dead (coma) and three (3) faced handi-
cap, an irreversible brain damage. In years 
2011 to 2015, approximately 20 deaths have 
been confirmed in the United States due to the 
extensive use of synthetic cannabinoids 
(Trecki et al., 2015), while more than 1000 
patients were in emergency visits. 
Potential biotechnological approach of  
cannabinoids 
To overcome the toxicity of synthetic can-
nabinoids, the area of cloning manifested a 
new scenario regarding biotechnological syn-
thesis of cannabinoids encoding gene THCA 
synthase (Sirikantaramas et al., 2004). Siri-
kantaramas et al. (2004) revealed tobacco 
long-haired roots could generate THCA syn-
thase, which is capable to produce THCA fol-
lowing nourishing of cannabichromenic acid 
(CBGA). Upon exposure to heat, THCA read-
ily converts to THC (Shoyama et al., 1977). 
Therefore, such biotechnological advance-
ment leads to produce THA, and then CBGA 
is easy to manufacture (Mechoulam and Ben-
Zvi, 1969; Yagen and Mechoulam, 1969). 
Hence, this is the need of time that further mo-
lecular studies have to be conducted with re-
gard to the biosynthesis of cannabinoids with-
out feeding of some precursors/initiators. Up 
till now, the cloning and characterization of 
THCA synthase is possible in the pathway. 
Previous studies had stated that for the clon-
ing of polyketide synthase, homology-based 
approach is not efficient (Raharjo et al., 
2004). So, metabolomics and proteomics are 
new branches of omics reported in C. Sativa, 
which can determine various types of metab-
olites unknown genes involved in the biosyn-
thesis of secondary precursors (Choi et al., 
2004). The key point of metabolomics and 
transcriptomics are particularly applied for 
the purpose of diagnosing specific disease due 
to the ability of this advanced technology to 
accurately detect the reasons, which represent 
the external changes (Rischer et al., 2006; 
Tohge et al., 2005; Ziegler et al., 2006). The 
metabolomics experiments are carried out 
through either the use of mass spectrometry 
(MS) or nuclear magnetic resonance (NMR) 
techniques, which open a way to identify can-
nabinoid biosynthesis pathway. 
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Table 1: Pathological findings, the cause and manner of death, a comparison of cannabinoids toxicity 
with other drug intoxication 
No. Age 
and 
gender 
Pathological lesions Cause of death Manner 
of death 
1 55 Male 
(M) 
Rigor mortis, coronary disease, 
Obesity, diabetes type-2, Choleli-
thiasis 
Obesity, ischemic heart dis-
ease, cannabinoids toxicity 
Natural 
2 34 M Not presented Synthetic cannabinoid and  
alcohol toxicity 
Toxicity 
3 21 M Congestive lungs, vomiting, pneu-
monia, patchy alveolar hemor-
rhages 
Alcohol, THC drug toxicity Accident 
4 15 fe-
males 
(F) 
No findings Various injuries Accident 
5 52 M No autopsy Various force damages Accident 
6 61 F No evidences Cardiovascular disease Natural 
7 29 M Coronary artery disease, various 
sharp force damages to foot 
Cardiovascular anomalies Natural 
8 55 M Hypertension, blunt force injury to 
the head, pulmonary emphysema, 
obesity, hemangioma in the liver 
Hypertensive disease, head in-
juries, synthetic cannabinoids 
Natural 
9 25 M No evidence Irreversible brain damages due 
to the synthetic cannabinoids 
toxicity 
Accident 
10 17 M Not provided Sudden death due to canna-
binoids usage 
Accident 
11 25 M Pulmonary edema, Foam in exter-
nal nares 
Adverse drug intoxication Accident 
12 42 F Lung congestion, fatty liver, cardio-
megaly, chronic obstructive pulmo-
nary disease, arteriosclerosis 
Synthetic cannabinoids’  
toxicity 
Accident 
13 15 M Alteration in renal function Synthetic marijuana Accident 
14 56 F Not mentioned Carcinoma in breast, diabetes, 
synthetic cannabinoids 
Natural 
15 M Congested lungs, frothy airways, 
lesions in brain, variable discolora-
tion of liver 
Oxycodone and fluoxetine  
toxicity 
Uncertain 
16 24 M Not mentioned Synthetic cannabinoids, her-
oin, hydrocodone and alprazo-
lam intoxication 
Accident 
17 38 M Not mentioned Synthetic cannabinoids,  
phenobarbital and methadone 
toxicity 
Accident 
18 24 M Cardiomegaly, froth in respiratory 
tract 
Adverse effect of synthetic 
cannabinoids 
Accident 
19 41 M Cardiomegaly, hallucination Confined situation due to the 
arrest by police, synthetic ma-
rijuana usage 
Unknown 
20 23 M Not mentioned High fever, hallucination, syn-
thetic marijuana usage, social 
complications 
Unknown 
21 25 M Rigor mortis Complications due to synthetic 
cannabinoids, Ethanol toxicity, 
Hypothermia 
Accident 
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No. Age 
and 
gender 
Pathological lesions Cause of death Manner 
of death 
22 42 M Congestive pulmonary edema, 
obesity, cardiomegaly, coronary 
artery atherosclerosis, hepatomeg-
aly with steatosis, splenomegaly, 
cholesterolosis 
Various drugs’ intoxication Accident 
23 58 M Atherosclerosis, cardiac  
hypertrophy 
Coronary artery thrombi lead 
to acute myocardial infarction 
Natural 
24 31 F Subdural hemorrhages, pelvic 
fracture, liver slash, facial and  
elbow fracture 
Multiple blunted traumatic 
damages, Acute drug mixed 
intoxication 
Accident 
25 30 F Complete blockage of the left ante-
rior descending coronary artery 
due to a thrombus 
Acute myocardial infarction Natural 
 
 
 
Plant transformation and regeneration 
hindered genetic engineering in C. Sativa. To 
approach this, Agrobacterium tumefaciens is 
used, which potentially transforms C. Sativa 
suspension culture genetically (Feeney and 
Punja, 2003). Though, the suspension was not 
capable to synthesize cannabinoids like 
THCA and cannabidiolic acid (CBDA). Fur-
thermore, genetic engineering was challeng-
ing in the culture suspension due to canna-
binoids toxicity to C. Sativa. The main pur-
pose of biotechnological approaches is to pro-
duce transgenic C. Sativa, but regeneration of 
C. Sativa is very tough except the formation 
of somatic embryogenesis from callus (Petri, 
1988). Hence, in specific heterologous plants, 
biomimetic production of cannabinoids 
would be of interest and applicable. Due to 
the toxicity of cannabinoids, that would be 
better to perform such procedures in specific 
organs like glandular trichomes, which is con-
sidered for gene expression.  
In many countries cultivation and posses-
sion of C. Sativa is illegal. The identification 
of such drug materials in grabbed samples is 
critical. The use of anti-THCA monoclonal 
antibody (MAb) is a landmark for determina-
tion of a type of C. Sativa (Goto et al., 1994; 
Tanaka et al., 1996). As, all cannabinoids are 
cross active to MAb, however, it is just re-
stricted to cannabinoids, C. Sativa and its pro-
duction can be identified from other plants 
(Sirikantaramas et al., 2007). Therefore, the 
use of MAb is an indicator of all THC metab-
olites and it will be a decent screening marker 
for marihuana consumers (Watanabe et al., 
2000). 
Another classical determination method 
for cannabinoids depends on the pollen pro-
tein using anti-pollen IgE (Tanaka et al., 
1998). The theory behind this method is to 
distinguish the pollen of C. Sativa in the mix-
ture of the other plants’ pollen, by the use of 
deoxyribonucleic acid (DNA) polymorphism 
of TCHA synthase, which identifies two var-
iants such as C. Sativa drug and fiber type in 
the mixture. This would be possible through 
the cloning of THCA synthase. A particular 
polymerase chain reaction (PCR) marker of 
THCA to distinguish drug type strains has 
been effectively established (Kojoma et al., 
2006; Pacifico et al., 2006). 
In area of the drug development, altera-
tion associated with spatial memory has also 
been explored in the pharmacological field 
(Egashira et al., 2006). Moreover, study sug-
gested that arachidonic acid cascade plays s 
vital role in dependency and withdrawal from 
abused drugs like cannabinoid, opioid and 
psycho-stimulants (Anggadiredja et al., 
2003). Thus, in the endo-cannabinoid system, 
arachidonic acid cascade assists in the initia-
tion of restoring effect of methamphetamine-
primingand signals (Anggadiredja et al., 
2003). This shows that endo-cannabinoid ac-
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tivating compounds like cyclooxygenase in-
hibitors would be working as an antirelapse 
agent (Anggadiredja et al., 2004). These 
novel pharmacological phenomena and bio-
technological applications would provide bet-
ter combined results, which developed canna-
binoid drugs might be appreciated in future 
without showing toxicity. 
 
Regulations about the use of cannabinoids 
in different countries around the world 
The use of cannabinoids (cannabis) has 
been reported worldwide. A survey conducted 
in 2009, provided a rough estimate of users 
according to region and sub-region. The utili-
zation of cannabinoids have been legalized in 
several countries including; Austria, Ger-
many, Canada, Finland, Italy, Netherlands, Is-
rael, and many others, whereas possession or 
trade of these compounds is considered illegal 
in elsewhere (Parry and Myers, 2014). How-
ever, it has not been approved by the United 
State Food and Drug Administration (FDA). 
For instance, the users of cannabis in Aus-
tralia are facing some penalties such as cau-
tioning, heavy fines and imprisonment; de-
pending on the state, age of the individual 
user and the amount of possession (Campbell, 
2001; Barratt et al., 2013). Figure 4 provides 
a summary of some countries that possession 
or trade of these compounds is considered le-
gal or illegal. 
 
CONCLUSION 
It is concluded that specific synthetic can-
nabinoids possess poor responses towards 
CB1 or CB2 receptors, while some synthetic 
members like Δ9-THC exhibit high affinity to 
these receptors. That might be due to the fact 
that cannabinoids initiate immune modula-
tory effects without any psychological signs. 
They play potential and effective roles in cer-
tain autoimmune diseases. Only few studies 
are available regarding immunosuppressive 
properties of cannabinoids, still further pin-
point and accurate investigations are required. 
Cannabinoids have shown direct or indirect 
association with mortality, however, their us-
age should be defined during post-mortem  
 
 
Figure 4: Countries where possession or trade of cannabinoids is considered legal or illegal (www.map-
sofworld.com)
Countries that  
approved use 
Countries that  
disapproved use 
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of various cases, when specified by explora-
tory and case history. It is clear that the ex-
treme use of cannabis and cannabinoids con-
veys risks, both to the public and the habitual 
users. Therapeutic applications of such com-
pounds need careful attention and critical sci-
entific point of view. Studying the effects of 
natural cannabinoids and more importantly 
the synthetic types (due to their higher tox-
icity) on the receptors could help clinicians 
to govern the adverse incidence and expand 
the pharmacological and medicinal applica-
tions associated with them.  
Challenges like the safety profile of these 
compounds, complete understanding of their 
biosynthetic pathways and the activities of the 
enzymes and receptors involved in their me-
tabolism throughout the body remain to be re-
solved. In order to use the biotechnological 
techniques for cannabinoid production is pos-
sible to overcome the toxicity. In this manner, 
the application of biotechnological tech-
niques like cloning and monoclonal antibody 
practices to improve the synthesis of canna-
binoids like the encoding gene for THCA syn-
thase might help to overcome the toxicity of 
these compounds. The combination of phar-
macological and biotechnological applica-
tions might lead to the development of some 
cannabinoid drugs in future without showing 
toxicity. Further experimental studies and 
case reports are needed for the toxicologists 
and forensic pathologists to determine the 
specific cause of death from the case history, 
biopsy, clinical findings and post mortem le-
sions.  
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